Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.

Biological Aspects

Cytokines as Mediators of Hypercalcemia of Malignancy
Humoral Hypercalcemia of Malignancy: Role of Parathyroid Hormone-Related Protein
In Vivo Models of Hypercalcemia of Malignancy
Morphological Characteristics of Tumors with Humoral Hypercalcemia of Malignancy: Functional Morphology of PTHrP
Clinical Aspects
Epidemiological Aspects of Hypercalcemia of Malignancy
Clinical Picture of Humoral Hypercalcemia of Malignancy
Hypercalcemia Associated with Hematologic Malignancies
Differential Diagnosis of Hypercalcemia: Laboratory Assessment
Drug Therapy of Hypercalcemia Due to Malignancy.